Comparing Legend Biotech (NASDAQ:DADA) & Alphabet (NASDAQ:GOOGL)

Legend Biotech (NASDAQ:DADA) and Alphabet (NASDAQ:GOOGL) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Institutional & Insider Ownership

14.5% of Legend Biotech shares are owned by institutional investors. Comparatively, 33.8% of Alphabet shares are owned by institutional investors. 11.7% of Alphabet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Legend Biotech and Alphabet’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Legend Biotech $437.76 million 13.96 -$235.82 million ($3.84) -7.16
Alphabet $161.86 billion 6.45 $34.34 billion $51.56 29.77

Alphabet has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Alphabet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Legend Biotech and Alphabet, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech 0 1 0 0 2.00
Alphabet 0 3 40 0 2.93

Legend Biotech currently has a consensus target price of $22.00, indicating a potential downside of 20.00%. Alphabet has a consensus target price of $1,667.69, indicating a potential upside of 8.64%. Given Alphabet’s stronger consensus rating and higher possible upside, analysts plainly believe Alphabet is more favorable than Legend Biotech.

Profitability

This table compares Legend Biotech and Alphabet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Legend Biotech N/A N/A N/A
Alphabet 18.99% 15.62% 11.56%

Summary

Alphabet beats Legend Biotech on 12 of the 13 factors compared between the two stocks.

Legend Biotech Company Profile

New Dada owns and operates an online crowdsourcing logistics portal and provides local instant delivery service. The company was formerly known as Dada Nexus Limited and changed its name to New Dada in April 2016. New Dada was founded in 2014 and is based in Shanghai, China.

Alphabet Company Profile

Alphabet Inc., through its subsidiaries, provides online advertising services in the United States and internationally. The company offers performance and brand advertising services. It operates through Google and Other Bets segments. The Google segment includes principal Internet products, such as Ads, Android, Chrome, Commerce, Google Cloud, Google Maps, Google Play, Hardware, Search, and YouTube, as well as technical infrastructure and newer efforts, including Virtual Reality. This segment also offers digital content, enterprise cloud services, and hardware products, as well as other miscellaneous products and services. The Other Bets segment includes businesses, such as Access, Calico, CapitalG, GV, Nest, Verily, Waymo, and X, as well as fiber Internet and Television services. Alphabet Inc. was founded in 1998 and is headquartered in Mountain View, California.

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.